Table 3.
Outcomes in terms of the amisulpride intervention.
Variable | OR or coefficient | 95% CI |
---|---|---|
Primary outcome | ||
>20% reduction in PANSS from baseline (OR) | 1.17 | (0.40, 3.42) |
Secondary outcomes | ||
PANSS negative symptom subscale | −0.71 | (−3.22, 1.81) |
Service engagement: SES | 1.17 | (−1.63, 3.97) |
Depression: CDSS | 0.23 | (−1.54, 2.00) |
Insight: SAI | 0.02 | (−1.33, 1.37) |
Side effects | ||
Non neurological | ||
ANNSERS-E | 1.58 | (−3.60, 6.76) |
Metabolic/endocrine side effects | ||
Weight | 0.79 | (−1.40, 2.99) |
Body mass index | −0.02 | (−1.05, 1.01) |
Waist circumference | 1.05 | (−2.33, 4.42) |
Systolic blood pressure (mmHg) | 3.49 | (−3.66, 10.63) |
Diastolic blood pressure (mmHg) | 3.33 | (−1.65, 8.31) |
Serum prolactin (ng/ml) | 50.47 | (−8.86, 109.80) |
Ln* serum prolactin | 1.43 | (0.71, 2.14) |
Plasma glucose (mmol/liter): nonfasting blood sample | 0.66 | (−0.22, 1.54) |
Total cholesterol (mmol/liter) | 0.48 | (−0.11, 1.07) |
HDL cholesterol (mmol/liter) | 0.09 | (−0.23, 0.41) |
LDL cholesterol (mmol/liter) | 0.11 | (−0.62, 0.85) |
Triglycerides (mmol/liter) | 0.78 | (−0.10, 1.65) |
Motor side effects | ||
BARS: akathisia present$ (global item score ⩾2) (OR) | 0.35 | (0.06, 2.09) |
Tardive dyskinesia: AIMS positive$ (OR) | 0.37 | (0.03, 4.34) |
EPSE | −0.04 | (−0.22, 0.14) |
Parkinsonism present (total score ⩾3)$ (OR) | 0.63 | (0.18, 2.20) |
Logarithmic transformation.
Unadjusted result, too few events to do an adjusted analysis.
AIMS, Abnormal Involuntary Movement Scale; ANNSERS-E, Antipsychotic Non-Neurological Side Effects Scale enhanced version; BARS, Barnes Akathisia Rating Scale; CDSS, Calgary Depression Rating Scale for Schizophrenia; CI, confidence interval; EPSE, Extrapyramidal Side Effects Scale; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OR, odds ratio, all other results are coefficients; PANSS, Positive and Negative Syndrome Scale; SAI, Schedule for the Assessment of Insight; SES, Service Engagement Scale.